Effect of Anti-osteoporotic Medications on Hepatic Steatosis and Fibrosis of Women with Postmenopausal Osteoporosis and Nonalcoholic Fatty Liver Disease

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Denosumab (Primary) ; Alendronic acid; Calcium carbonate; Colecalciferol
Indications Non-alcoholic fatty liver disease; Postmenopausal osteoporosis
Focus Therapeutic Use
Acronyms OsteoNAFLD

16 Dec 2024 Planned End Date changed from 1 Dec 2025 to 1 Sep 2026.
16 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Sep 2025.
26 Jul 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com